Symbols / PYXS
PYXS Chart
About
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 92.15M |
| Enterprise Value | 34.97M | Income | -97.09M | Sales | 2.82M |
| Book/sh | 1.11 | Cash/sh | 1.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 44 | IPO | — |
| P/E | — | Forward P/E | -1.25 | PEG | — |
| P/S | 32.68 | P/B | 1.34 | P/C | — |
| EV/EBITDA | -0.43 | EV/Sales | 12.40 | Quick Ratio | 3.93 |
| Current Ratio | 4.29 | Debt/Eq | 27.73 | LT Debt/Eq | — |
| EPS (ttm) | -1.58 | EPS next Y | -1.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-18 | ROA | -34.33% |
| ROE | -87.28% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -29.30% | Profit Margin | 0.00% | Shs Outstand | 62.26M |
| Shs Float | 39.83M | Short Float | 4.63% | Short Ratio | 1.77 |
| Short Interest | — | 52W High | 5.55 | 52W Low | 0.83 |
| Beta | 1.46 | Avg Volume | 1.25M | Volume | 336.11K |
| Target Price | $6.92 | Recom | None | Prev Close | $1.45 |
| Price | $1.48 | Change | 2.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.93
Mean price target
2. Current target
$1.48
Latest analyst target
3. DCF / Fair value
$-11.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.48
Low
$5.00
High
$9.00
Mean
$6.93
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-19 | main | RBC Capital | Outperform → Outperform | $5 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-11-24 | main | Stephens & Co. | Overweight → Overweight | $8 |
| 2025-11-04 | main | Guggenheim | Buy → Buy | $7 |
| 2025-09-04 | init | Guggenheim | — → Buy | $5 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-19 | reit | RBC Capital | Outperform → Outperform | $8 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-20 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-20 | reit | RBC Capital | Outperform → Outperform | $8 |
| 2024-11-21 | main | RBC Capital | Outperform → Outperform | $10 |
| 2024-11-21 | down | William Blair | Outperform → Market Perform | — |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-08 | init | Stephens & Co. | — → Overweight | $13 |
| 2024-09-19 | reit | RBC Capital | Outperform → Outperform | $7 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-08 | init | Stifel | — → Buy | $10 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
- Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com hu, 18 Dec 2025 08
- Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
- Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Stock Titan hu, 09 Oct 2025 07
- Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance ue, 14 Oct 2025 07
- Pyxis Oncology Announces Interim CEO Amid Leadership Transition - The Globe and Mail Sat, 07 Feb 2026 08
- New Analyst Forecast: $PYXS Given $5 Price Target - Quiver Quantitative Fri, 19 Dec 2025 08
- Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross? - Zacks Investment Research Mon, 15 Sep 2025 07
- Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - Nasdaq Sun, 16 Nov 2025 08
- Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints - Endpoints News hu, 18 Dec 2025 08
- Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS) - Seeking Alpha Fri, 12 Sep 2025 07
- Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire ue, 03 Feb 2026 08
- Stephens raises Pyxis Oncology stock price target to $8 on MICVO potential - Investing.com Mon, 24 Nov 2025 08
- Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross? - Yahoo Finance Mon, 15 Sep 2025 07
- Guggenheim Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq ue, 04 Nov 2025 08
- ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan Mon, 13 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 88850 | 174364 | — | Purchase at price 1.96 - 2.00 per share. | CONNEALY PAMELA ANN | Chief Operating Officer | — | 2024-11-26 00:00:00 | I |
| 1 | 6000 | — | — | Stock Award(Grant) at price 0.00 per share. | PALANI SANTHOSH | Director | — | 2024-06-07 00:00:00 | D |
| 2 | 35219 | — | — | Stock Award(Grant) at price 0.00 per share. | FLAVIN JOHN L. | Director | — | 2024-03-26 00:00:00 | D |
| 3 | 35219 | — | — | Stock Award(Grant) at price 0.00 per share. | LEWIS-HALL FREDA C | Director | — | 2024-03-26 00:00:00 | D |
| 4 | 38741 | — | — | Stock Award(Grant) at price 0.00 per share. | HUMPHREY RACHEL W M.D. | Director | — | 2024-03-26 00:00:00 | D |
| 5 | 38741 | — | — | Stock Award(Grant) at price 0.00 per share. | DUPONT JAKOB | Director | — | 2024-03-26 00:00:00 | D |
| 6 | 35219 | — | — | Stock Award(Grant) at price 0.00 per share. | CLINE DARREN S | Director | — | 2024-03-26 00:00:00 | D |
| 7 | 131484 | — | — | Stock Award(Grant) at price 0.00 per share. | WADHANE JITENDRA | Officer | — | 2024-03-26 00:00:00 | D |
| 8 | 328710 | — | — | Stock Award(Grant) at price 0.00 per share. | CONNEALY PAMELA ANN | Chief Operating Officer | — | 2024-03-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -545.06K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.03 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -44.55M | -80.27M | -122.77M | -62.84M |
| TotalUnusualItems | -20.96M | 0.00 | -6.23M | |
| TotalUnusualItemsExcludingGoodwill | -20.96M | 0.00 | -6.23M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -77.33M | -73.79M | -120.72M | -75.97M |
| ReconciledDepreciation | 2.98M | 1.93M | 709.00K | 647.00K |
| ReconciledCostOfRevenue | 475.00K | 0.00 | ||
| EBITDA | -65.51M | -80.27M | -122.77M | -69.07M |
| EBIT | -68.50M | -82.20M | -123.48M | -69.72M |
| NetInterestIncome | 7.04M | 6.63M | 2.76M | 23.00K |
| InterestIncome | 7.04M | 6.63M | 2.76M | 23.00K |
| NormalizedIncome | -56.91M | -73.79M | -120.72M | -69.74M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -77.33M | -73.79M | -120.72M | -75.97M |
| TotalExpenses | 84.64M | 82.20M | 123.48M | 69.72M |
| TotalOperatingIncomeAsReported | -89.46M | -82.20M | -123.48M | -69.72M |
| DilutedAverageShares | 58.45M | 39.90M | 33.03M | 8.49M |
| BasicAverageShares | 58.45M | 39.90M | 33.03M | 8.49M |
| DilutedEPS | -1.32 | -1.85 | -3.65 | -8.95 |
| BasicEPS | -1.32 | -1.85 | -3.65 | -8.95 |
| DilutedNIAvailtoComStockholders | -77.33M | -73.79M | -120.72M | -75.97M |
| NetIncomeCommonStockholders | -77.33M | -73.79M | -120.72M | -75.97M |
| NetIncome | -77.33M | -73.79M | -120.72M | -75.97M |
| NetIncomeIncludingNoncontrollingInterests | -77.33M | -73.79M | -120.72M | -75.97M |
| NetIncomeContinuousOperations | -77.33M | -73.79M | -120.72M | -75.97M |
| TaxProvision | -2.16M | 0.00 | ||
| PretaxIncome | -79.50M | -73.79M | -120.72M | -75.97M |
| OtherIncomeExpense | -18.04M | 1.78M | -6.28M | |
| OtherNonOperatingIncomeExpenses | 2.93M | 1.78M | 181.00K | |
| SpecialIncomeCharges | -20.96M | 0.00 | ||
| ImpairmentOfCapitalAssets | 20.96M | 0.00 | ||
| EarningsFromEquityInterest | 0.00 | -231.00K | ||
| GainOnSaleOfSecurity | -6.23M | |||
| NetNonOperatingInterestIncomeExpense | 7.04M | 6.63M | 2.76M | 23.00K |
| InterestIncomeNonOperating | 7.04M | 6.63M | 2.76M | 23.00K |
| OperatingIncome | -68.50M | -82.20M | -123.48M | -69.72M |
| OperatingExpense | 84.17M | 82.20M | 123.48M | 69.72M |
| ResearchAndDevelopment | 58.75M | 49.59M | 86.13M | 51.05M |
| SellingGeneralAndAdministration | 25.42M | 32.61M | 37.35M | 18.66M |
| GeneralAndAdministrativeExpense | 25.42M | 32.61M | 37.35M | 18.66M |
| OtherGandA | 4.49M | 6.35M | 13.06M | 10.04M |
| InsuranceAndClaims | 5.15M | 5.17M | 5.56M | |
| SalariesAndWages | 15.78M | 21.09M | 18.73M | 8.62M |
| GrossProfit | 15.67M | 0.00 | ||
| CostOfRevenue | 475.00K | 0.00 | ||
| TotalRevenue | 16.15M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 16.15M | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 59.97M | 44.75M | 34.96M | 32.22M |
| ShareIssued | 59.97M | 44.75M | 34.96M | 32.22M |
| TotalDebt | 20.20M | 21.33M | 18.92M | 165.00K |
| TangibleBookValue | 118.15M | 101.40M | 160.82M | 261.31M |
| InvestedCapital | 120.75M | 125.70M | 160.82M | 261.31M |
| WorkingCapital | 114.76M | 98.84M | 154.98M | 259.96M |
| NetTangibleAssets | 118.15M | 101.40M | 160.82M | 261.31M |
| CapitalLeaseObligations | 20.20M | 21.33M | 18.92M | 165.00K |
| CommonStockEquity | 120.75M | 125.70M | 160.82M | 261.31M |
| TotalCapitalization | 120.75M | 125.70M | 160.82M | 261.31M |
| TotalEquityGrossMinorityInterest | 120.75M | 125.70M | 160.82M | 261.31M |
| StockholdersEquity | 120.75M | 125.70M | 160.82M | 261.31M |
| GainsLossesNotAffectingRetainedEarnings | 170.00K | 63.00K | 0.00 | |
| OtherEquityAdjustments | 170.00K | 63.00K | ||
| RetainedEarnings | -363.56M | -286.23M | -212.44M | -91.72M |
| AdditionalPaidInCapital | 484.08M | 411.82M | 373.23M | 353.00M |
| CapitalStock | 60.00K | 45.00K | 34.00K | 32.00K |
| CommonStock | 60.00K | 45.00K | 34.00K | 32.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 36.43M | 48.02M | 50.55M | 18.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.75M | 22.26M | 18.92M | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 2.16M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 2.16M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 18.75M | 20.10M | 18.92M | 0.00 |
| LongTermCapitalLeaseObligation | 18.75M | 20.10M | 18.92M | 0.00 |
| CurrentLiabilities | 17.68M | 25.76M | 31.63M | 18.71M |
| OtherCurrentLiabilities | 643.00K | 356.00K | 1.09M | 266.00K |
| CurrentDeferredLiabilities | 0.00 | 7.66M | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 7.66M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 1.45M | 1.23M | 165.00K | |
| CurrentCapitalLeaseObligation | 1.45M | 1.23M | 0.00 | 165.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.98M | 5.22M | 4.24M | 2.96M |
| PayablesAndAccruedExpenses | 11.60M | 11.29M | 26.30M | 15.31M |
| CurrentAccruedExpenses | 6.75M | 7.40M | 19.21M | 3.36M |
| Payables | 4.86M | 3.90M | 7.10M | 11.95M |
| AccountsPayable | 4.86M | 3.90M | 7.10M | 11.95M |
| TotalAssets | 157.18M | 173.73M | 211.38M | 280.02M |
| TotalNonCurrentAssets | 24.74M | 49.12M | 24.77M | 1.35M |
| OtherNonCurrentAssets | 109.00K | |||
| GoodwillAndOtherIntangibleAssets | 2.60M | 24.31M | 0.00 | |
| OtherIntangibleAssets | 2.60M | 24.31M | ||
| NetPPE | 22.14M | 24.81M | 24.77M | 1.24M |
| AccumulatedDepreciation | -5.23M | -3.60M | -1.82M | -1.12M |
| GrossPPE | 27.37M | 28.42M | 26.59M | 2.35M |
| Leases | 10.74M | 10.96M | 530.00K | 225.00K |
| ConstructionInProgress | 0.00 | 9.18M | 0.00 | |
| OtherProperties | 15.60M | 16.34M | 15.85M | 2.04M |
| MachineryFurnitureEquipment | 1.03M | 1.12M | 1.04M | 94.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 132.44M | 124.60M | 186.61M | 278.67M |
| OtherCurrentAssets | 3.28M | 2.82M | 3.94M | 84.00K |
| RestrictedCash | 1.47M | 1.47M | 1.47M | 1.47M |
| PrepaidAssets | 761.00K | 1.01M | 1.31M | 2.38M |
| Receivables | 21.00K | 598.00K | 0.00 | |
| AccruedInterestReceivable | 21.00K | 598.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 126.93M | 119.30M | 179.29M | 274.74M |
| OtherShortTermInvestments | 107.46M | 109.63M | 0.00 | |
| CashAndCashEquivalents | 19.47M | 9.66M | 179.29M | 274.74M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -57.91M | -77.44M | -95.73M | -35.87M |
| IssuanceOfCapitalStock | 59.05M | 6.12M | 0.00 | 303.88M |
| CapitalExpenditure | -237.00K | -6.73M | -6.40M | -540.00K |
| InterestPaidSupplementalData | 10.00K | 1.00K | ||
| IncomeTaxPaidSupplementalData | 164.00K | 48.00K | 17.00K | 0.00 |
| EndCashPosition | 20.95M | 11.14M | 180.76M | 276.32M |
| BeginningCashPosition | 11.14M | 180.76M | 276.32M | 8.19M |
| ChangesInCash | 9.81M | -169.63M | -95.55M | 268.13M |
| FinancingCashFlow | 59.33M | 5.93M | 183.00K | 304.04M |
| CashFlowFromContinuingFinancingActivities | 59.33M | 5.93M | 183.00K | 304.04M |
| NetOtherFinancingCharges | -240.00K | -445.00K | ||
| ProceedsFromStockOptionExercised | 520.00K | 252.00K | 183.00K | 167.00K |
| NetPreferredStockIssuance | 0.00 | 151.58M | ||
| PreferredStockIssuance | 0.00 | 151.58M | ||
| NetCommonStockIssuance | 59.05M | 6.12M | 0.00 | 152.30M |
| CommonStockIssuance | 59.05M | 6.12M | 0.00 | 152.30M |
| InvestingCashFlow | 8.15M | -104.85M | -6.40M | -590.00K |
| CashFlowFromContinuingInvestingActivities | 8.15M | -104.85M | -6.40M | -590.00K |
| NetInvestmentPurchaseAndSale | 8.39M | -104.78M | 0.00 | |
| SaleOfInvestment | 168.51M | 92.05M | 0.00 | |
| PurchaseOfInvestment | -160.12M | -196.83M | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 6.66M | 0.00 | -50.00K |
| SaleOfBusiness | 0.00 | 6.66M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -50.00K | ||
| NetPPEPurchaseAndSale | -237.00K | -6.73M | -6.40M | -540.00K |
| PurchaseOfPPE | -237.00K | -6.73M | -6.40M | -540.00K |
| OperatingCashFlow | -57.67M | -70.71M | -89.33M | -35.33M |
| CashFlowFromContinuingOperatingActivities | -57.67M | -70.71M | -89.33M | -35.33M |
| ChangeInWorkingCapital | -11.82M | -11.66M | 4.50M | 6.68M |
| ChangeInOtherWorkingCapital | -9.92M | 998.00K | ||
| ChangeInOtherCurrentLiabilities | -1.23M | 2.41M | 4.26M | -615.00K |
| ChangeInPayablesAndAccruedExpense | -470.00K | -17.60M | 3.62M | 9.73M |
| ChangeInAccruedExpense | -1.67M | -14.10M | 11.95M | 5.09M |
| ChangeInPayable | 1.20M | -3.51M | -8.33M | 4.64M |
| ChangeInAccountPayable | 1.20M | -3.51M | -8.33M | 4.64M |
| ChangeInPrepaidAssets | -203.00K | 2.53M | -3.38M | -2.44M |
| OtherNonCashItems | 700.00K | 660.00K | 10.41M | 20.60M |
| StockBasedCompensation | 12.95M | 16.95M | 15.76M | 6.44M |
| AssetImpairmentCharge | 20.96M | 0.00 | ||
| AmortizationOfSecurities | -6.11M | -4.79M | 0.00 | |
| DepreciationAmortizationDepletion | 2.98M | 1.93M | 709.00K | 647.00K |
| DepreciationAndAmortization | 2.98M | 1.93M | 709.00K | 647.00K |
| OperatingGainsLosses | 6.28M | |||
| EarningsLossesFromEquityInvestments | 0.00 | 50.00K | ||
| GainLossOnInvestmentSecurities | 6.23M | |||
| NetIncomeFromContinuingOperations | -77.33M | -73.79M | -120.72M | -75.97M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PYXS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|